Biograph 55

Developing a novel cancer immunotherapy. The lead program, B%%-001 is a bispecific antibody that targets a unique regulatory B-cell (B-reg) population found in solid tumors and has the potential to address the unmet need of cancer patients who do not respond to the current standard of checkpoint. It is also being developed to eliminate plasma cells involved in autoimmune diseases